Literature DB >> 25297015

CGRP as a new target in prevention and treatment of migraine.

Hans-Christoph Diener1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25297015     DOI： 10.1016/S1474-4422(14)70228-5

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  8 in total

Review 1.  Migraine: multiple processes, complex pathophysiology.

Authors:  Rami Burstein; Rodrigo Noseda; David Borsook
Journal:  J Neurosci       Date:  2015-04-29       Impact factor: 6.167

Review 2.  Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.

Authors:  Martina Curto; Luana Lionetto; Francesco Fazio; Dimos-Dimitrios Mitsikostas; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2015-02-24       Impact factor: 3.397

3.  Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.

Authors:  Xing Wang; Qiang He; Dingke Wen; Lu Ma; Chao You
Journal:  Neurol Sci       Date:  2021-11-03       Impact factor: 3.830

Review 4.  The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.

Authors:  Bianca Raffaelli; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 5.  The Itch-Scratch Cycle: A Neuroimmune Perspective.

Authors:  Madison R Mack; Brian S Kim
Journal:  Trends Immunol       Date:  2018-11-21       Impact factor: 16.687

Review 6.  The metabolic face of migraine - from pathophysiology to treatment.

Authors:  Elena C Gross; Marco Lisicki; Dirk Fischer; Peter S Sándor; Jean Schoenen
Journal:  Nat Rev Neurol       Date:  2019-10-04       Impact factor: 42.937

7.  Bio-Oss® modified by calcitonin gene-related peptide promotes osteogenesis in vitro.

Authors:  Yuanjing Li; Lan Yang; Zhichao Zheng; Zhengmao Li; Tian Deng; Wen Ren; Caijuan Wu; Lvhua Guo
Journal:  Exp Ther Med       Date:  2017-08-28       Impact factor: 2.447

8.  Optimal Dose of Erenumab for Preventive Treatment of Episodic Migraine: A Systematic Review and Meta-Analysis.

Authors:  Yanbo Yang; Mingjia Chen; Da Wu; Yue Sun; Fan Jiang; Zhouqing Chen; Zhong Wang
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.